Key result
Urine toxicology shows ~73% baseline antihypertensive adherence with considerable intra-individual variation over 17 months.
Why the study?
Drug adherence may be a major problem in hypertension therapy and in diagnosing therapy resistance, and can be assessed directly using urine drug detection.
Population
18 patients with apparently treatment-resistant hypertension referred for renal denervation
Design
Pilot study
Follow-up
Up to 17 months
Authors
Loading...
Single-point adherence testing may miss variability in resistant hypertension; leaves open whether repeated toxicological assessment improves outcomes.
Observational (n=18)
In patients with apparently treatment-resistant hypertension, drug adherence varies considerably over time, highlighting the need for repeated adherence testing rather than relying on a single time point.
Wunder et al. (2019) conducted an observational in Apparently treatment-resistant hypertension (n=18). Antihypertensive drug adherence was evaluated on Adherence rate (percentage of number of detected vs. prescribed medical drugs). Antihypertensive drug adherence assessed by toxicological urine analysis showed a median baseline rate of 73.2% and exhibited considerable intra-individual variation over up to 17 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: